Warning! GuruFocus has detected 2 Severe warning signs with SGEN. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for SGEN (Seagen Inc) from 2001 to Apr 10 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Seagen stock (SGEN) PE ratio as of Apr 10 2021 is 43.29. More Details
Seagen PE Ratio (TTM) Historical Data
View and export this data going back to 2001. Start your Free Trial
Seagen PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
21823 - 30th Drive South East, Building 3, Bothell, WA, USA, 98021
Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.